Sensus Healthcare AI Stock Analysis
Want to see SRTS full AI Analyst Report?
Sensus Healthcare (SRTS) AI Stock Analysis
Sensus Healthcare
(NASDAQ:SRTS)
SRTS scores below average primarily due to deteriorating financial performance (shrinking revenue, sharply negative TTM margins, and heavy TTM cash burn). Technicals also weigh on the score as the stock trades below key moving averages with weak momentum. Offsetting these negatives, the company maintains very low leverage and the earnings call highlighted improving gross margin/adjusted EBITDA and potential reimbursement tailwinds, but execution and revenue conversion remain the key uncertainties.
Sensus Healthcare Key Performance Indicators (KPIs)
Revenue by GeographyBreaks down revenue across regions to show where Sensus earns its sales. For this small med‑tech firm, the split reveals dependence on key markets (and associated reimbursement or regulatory risk), highlights where expansion is succeeding, and signals how diversified the company’s growth prospects are.
Revenue is heavily China‑dependent, which creates the lumpy, high‑variance quarters and explains most of the recoveries after troughs; the occasional large “Other” spikes look like one‑off customer/timing events. The pronounced China drop in late‑2024 reads as a recognition/timing anomaly followed by a strong rebound through early 2026, supporting management’s view of sequential improvement, but international shipments and rental/Fair‑Deal mix have compressed ASPs and margins—geographic concentration keeps revenue volatile until recurring SensusLink/service revenue meaningfully ramps.
Sensus Healthcare (SRTS) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $38.27M
- Dividend Yield
- ―
- Average Volume (3M)
- 200.47K
- Price to Earnings (P/E)
- -2.4
- Beta (1Y)
- 0.19
- Revenue Growth
- -53.33%
- EPS Growth
- -429.93%
- Country
- US
- Employees
- 60
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Sensus Healthcare Business Overview & Revenue Model
Company Description
Sensus Healthcare, Inc. operates as a medical technology enterprise, manufacturing and distributing radiation therapy apparatuses to medical institutions across the globe. The company's portfolio leverages superficial radiation therapy (SRT), a cutti...
How the Company Makes Money
Sensus Healthcare generates revenue primarily by selling radiation therapy systems to medical practices, clinics, and hospitals. In addition to upfront system sales, the company earns revenue from recurring and ancillary sources tied to its installed...
Sensus Healthcare Earnings Call Summary
The call was broadly constructive and focused on commercial progress, including the placement of the 1,000th system, higher shipments, stronger gross margin, improved adjusted EBITDA, broader customer engagement, recurring revenue initiatives, and international opportunities. These positives were partially offset by a 13% revenue decline, a larger reported net loss, lower cash, delayed shipments from financing issues, and the need to convert the expanding pipeline into revenue.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management said its 5 priorities remain unchanged and that it expects to build on this momentum in the fourth quarter, while it “fully expect[s] that 26% to take effect on January 1 in the hospital environment” and confirmed this should occur on 1/1/'27; it also intends to be disciplined as it pursues international expansion, will attend conferences in Europe and Korea during the fourth quarter, aims to place SRT systems in every facility across groups with “about 450-or-more practices nationwide,” and said Sensus Link is seeing customers “all signing up for it.”
Sensus Healthcare Financial Statement Overview
Summary
Overall fundamentals are weak despite a low-debt balance sheet. The income statement has deteriorated materially (revenue down sharply from 2024 to 2025 and further in TTM; margins flipped from positive to deeply negative), and cash flow has turned to significant TTM cash burn. The balance sheet is a relative strength with minimal debt, but equity has declined and returns on equity are sharply negative, reflecting ongoing losses.
Income Statement
22NegativeBalance Sheet
72PositiveCash Flow
28Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 16.62M | 27.48M | 41.81M | 24.41M | 44.53M | 27.04M |
| Gross Profit | 6.95M | 11.87M | 24.43M | 14.06M | 29.63M | 16.99M |
| EBITDA | -11.35M | -9.00M | 9.45M | 1.11M | 28.50M | 4.73M |
| Net Income | -16.04M | -7.72M | 6.65M | 485.00K | 24.24M | 4.12M |
Balance Sheet | ||||||
| Total Assets | 40.55M | 53.04M | 62.16M | 53.71M | 56.73M | 32.24M |
| Cash, Cash Equivalents and Short-Term Investments | 12.92M | 22.08M | 22.06M | 23.15M | 25.52M | 14.52M |
| Total Debt | 278.00K | 680.00K | 602.00K | 783.00K | 1.02M | 225.00K |
| Total Liabilities | 5.11M | 4.94M | 6.34M | 4.87M | 8.67M | 6.22M |
| Stockholders Equity | 35.44M | 48.10M | 55.83M | 48.84M | 48.07M | 26.02M |
Cash Flow | ||||||
| Free Cash Flow | -11.51M | 332.00K | -1.11M | -2.37M | -1.57M | -414.00K |
| Operating Cash Flow | -11.35M | 528.00K | -831.00K | -2.15M | -1.41M | -286.00K |
| Investing Cash Flow | -174.00K | -196.00K | -276.00K | -187.00K | 14.84M | 129.00K |
| Financing Cash Flow | -5,000 | -305.00K | 15.00K | -40.00K | -2.43M | -231.00K |
Sensus Healthcare Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SRTS, the sentiment is Negative. The current price of 2.34 is below the 20-day moving average (MA) of 2.91, below the 50-day MA of 2.96, and below the 200-day MA of 3.42, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 35.96 is Neutral, neither overbought nor oversold. The STOCH value of 7.73 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SRTS.
Sensus Healthcare Risk Analysis
Sensus Healthcare disclosed 24 risk factors in its most recent earnings report. Sensus Healthcare reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
1 New RiskSensus Healthcare Peers Comparison
Overall Rating
INMD69Neutral
PEN67Neutral
SRTS48Neutral
ARAY41Neutral
IRIX40Underperform
NNOX40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 69Neutral | $763.61M | 10.79 | 11.36% | ― | 2.50% | -43.86% | |
| 67Neutral | $12.65B | 80.43 | 10.44% | ― | 16.98% | -5.62% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 48Neutral | $38.27M | -2.40 | -38.65% | ― | -53.33% | -429.93% | |
| 41Neutral | $8.40M | -0.48 | -36.60% | ― | -12.50% | 5.33% | |
| 40Underperform | $12.12M | -3.39 | -78.94% | ― | 3.68% | 36.91% | |
| 40Underperform | $25.36M | -0.19 | -94.35% | ― | 31.52% | -89.07% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SRTS | Sensus Healthcare, Inc. | 2.34 | -1.70 | -42.08% | |
| ARAY | Accuray Incorporated | 2.55 | -36.32 | -93.44% | |
| IRIX | Iridex | 0.69 | -0.24 | -26.13% | |
| PEN | Penumbra Inc. | 320.62 | 42.52 | 15.29% | |
| INMD | Inmode | 13.15 | -1.00 | -7.07% | |
| NNOX | Nano-X Imaging Ltd. | 0.32 | -2.99 | -90.33% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 14, 2026
